Clinical Trial Update: Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5 [Phase 3]

View source ↗

Summary

Phase 3 trial comparing telmisartan/hydrochlorothiazide 80/25 vs 80/12.5 in hypertension not responding to the lower-dose combination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Telmisartan/Hydrochlorothiazide 80/12.5 (telmisartan/hydrochlorothiazide)
• Telmisartan/Hydrochlorothiazide 80/25 (telmisartan/hydrochlorothiazide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension | Phase 3 | Status: COMPLETED